Acute Myeloid Leukemia, in Relapse Clinical Trials

42 clinical trials for Acute Myeloid Leukemia, in Relapse across international registries, including 20 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Master Framework For Relapse or Refractory Acute Myeloid Leukemia — RECRUITING
• A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia — RECRUITING · PHASE1
• A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia — RECRUITING · PHASE1
• A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS — RECRUITING · PHASE1
• Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML — RECRUITING · PHASE1
• Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML — RECRUITING · PHASE1
• Venetoclax to Augment Epigenetic Modification and Chemotherapy — RECRUITING · PHASE1
• Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML — RECRUITING · PHASE1
• Safety of MT-401-OTS in Patients With Relapsed AML or MDS — RECRUITING · PHASE1
• Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS — RECRUITING · PHASE1
• AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies — RECRUITING · PHASE1
• Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways — RECRUITING
• Off-the-shelf CD123 CAR-NK for R/R AML — RECRUITING · PHASE1
• A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) — RECRUITING · PHASE1
• Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen — RECRUITING · PHASE2
• Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) — RECRUITING · PHASE1
• Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• Lentivirally Redirected CD123 Autologous T Cells in AML — TERMINATED · PHASE1
• Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia — ACTIVE_NOT_RECRUITING · PHASE1
• A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia — COMPLETED · PHASE1
• KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia — COMPLETED · PHASE1
• A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies — NOT_YET_RECRUITING
• CD123 Redirected T Cells for AML in Pediatric Subjects — TERMINATED · PHASE1
• An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia — NOT_YET_RECRUITING · PHASE1
• Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML — NOT_YET_RECRUITING · PHASE2
• PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK) — TERMINATED · PHASE2
• Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia — COMPLETED · PHASE1
• CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia — TERMINATED · PHASE1
• High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML — COMPLETED · PHASE2
• CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) — WITHDRAWN · PHASE2
• Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia — TERMINATED · PHASE1
• Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) — OTHER · PHASE1
• A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML — TERMINATED · PHASE1
• Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome — COMPLETED · PHASE1
• Evaluation of the Safety and Efficacy of Esperanza Extract (PA001) — OTHER · PHASE1
• Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) — OTHER · PHASE1
• Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia — OTHER · PHASE2
• Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment — COMPLETED · PHASE1
• A Prospective, Interventional Study Assessing Response to Cytarabine, Daunorubicin and Etoposide (ADE) for First Relapse of Paediatric Acute Myeloid Leukemia — OTHER · PHASE2

Refine this search